Cognition Therapeutics Inc (NASDAQ: CGTX) on Friday, plunged -8.24% from the previous trading day, before settling in for the closing price of $0.39. Within the past 52 weeks, CGTX’s price has moved between $0.34 and $2.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 52.79%. With a float of $50.22 million, this company’s outstanding shares have now reached $59.85 million.
Let’s look at the performance matrix of the company that is accounted for 28 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Cognition Therapeutics Inc (CGTX) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cognition Therapeutics Inc is 18.96%, while institutional ownership is 8.23%. The most recent insider transaction that took place on Jan 31 ’25, was worth 30,001. In this transaction CEO & President of this company bought 38,851 shares at a rate of $0.77, taking the stock ownership to the 38,851 shares.
Cognition Therapeutics Inc (CGTX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 52.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 26.97% during the next five years compared to -16.44% drop over the previous five years of trading.
Cognition Therapeutics Inc (NASDAQ: CGTX) Trading Performance Indicators
Cognition Therapeutics Inc (CGTX) is currently performing well based on its current performance indicators. A quick ratio of 2.65 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.86, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.95 in one year’s time.
Technical Analysis of Cognition Therapeutics Inc (CGTX)
Cognition Therapeutics Inc (NASDAQ: CGTX) saw its 5-day average volume 0.81 million, a negative change from its year-to-date volume of 1.56 million. As of the previous 9 days, the stock’s Stochastic %D was 15.60%. Additionally, its Average True Range was 0.04.
During the past 100 days, Cognition Therapeutics Inc’s (CGTX) raw stochastic average was set at 2.01%, which indicates a significant decrease from 11.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 85.92% in the past 14 days, which was lower than the 96.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5255, while its 200-day Moving Average is $0.7451. Nevertheless, the first resistance level for the watch stands at $0.3811 in the near term. At $0.4081, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.4311. If the price goes on to break the first support level at $0.3311, it is likely to go to the next support level at $0.3081. The third support level lies at $0.2811 if the price breaches the second support level.
Cognition Therapeutics Inc (NASDAQ: CGTX) Key Stats
Market capitalization of the company is 21.95 million based on 61,973K outstanding shares. Right now, sales total 0 K and income totals -33,970 K. The company made 0 K in profit during its latest quarter, and -7,840 K in sales during its previous quarter.
